Department of Obstetrics and Gynecology, Sehit Prof Dr Ilhan Varank Sancaktepe Training and Research Hospital, Istanbul, Turkey.
J Ultrasound Med. 2021 Jan;40(1):191-203. doi: 10.1002/jum.15367. Epub 2020 Jun 1.
Lung ultrasound (LUS) is an effective tool to detect and monitor patients infected with 2019 coronavirus disease (COVID-19). The use of LUS on pregnant women is an emerging trend, considering its effectiveness during the outbreak. Eight pregnant women with a diagnosis of COVID-19 confirmed by nasal/throat real-time reverse transcription polymerase chain reaction testing who underwent point-of-care LUS examinations after routine obstetric ultrasound are described. A routinely performed LUS examination revealed serious lung involvement in 7 cases: 2 were initially asymptomatic; 3 have chest computed tomography; 1 had initial negative real-time reverse transcription polymerase chain reaction results; and 1 had initial negative computed tomographic findings. Treatment for COVID-19 was either commenced or changed in 87.5% of the patients (n = 7 of 8) on LUS findings. Among patients with abnormal LUS findings, treatment was commenced in 5 patients (71.5%) and changed in 2 patients (28.5%). One normal and 7 abnormal LUS cases indicate the impact of routine LUS on the clinical outcome and treatment of pregnant women.
肺部超声（LUS）是一种用于检测和监测感染 2019 年冠状病毒病（COVID-19）患者的有效工具。考虑到其在疫情期间的有效性，LUS 在孕妇中的应用是一种新兴趋势。本文介绍了 8 例经鼻/咽实时逆转录聚合酶链反应检测确诊为 COVID-19 的孕妇，她们在常规产科超声检查后进行了即时护理 LUS 检查。常规进行的 LUS 检查显示 7 例严重的肺部受累：2 例最初无症状；3 例有胸部计算机断层扫描；1 例最初实时逆转录聚合酶链反应结果为阴性；1 例最初计算机断层扫描结果为阴性。根据 LUS 结果，87.5%（n=7/8）的患者开始或改变了 COVID-19 的治疗方案。在 LUS 检查结果异常的患者中，有 5 例（71.5%）开始治疗，2 例（28.5%）改变治疗方案。1 例 LUS 正常和 7 例 LUS 异常病例表明常规 LUS 对孕妇的临床结局和治疗有影响。
